Profile for China Patent: 102458109

US Patent Family Members and Approved Drugs for China Patent: 102458109

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
10,010,517	Apr 29, 2030	Amarin Pharms	VASCEPA	icosapent ethyl
10,842,766	Apr 29, 2030	Amarin Pharms	VASCEPA	icosapent ethyl
10,881,632	Apr 29, 2030	Amarin Pharms	VASCEPA	icosapent ethyl
11,103,477	Apr 29, 2030	Amarin Pharms	VASCEPA	icosapent ethyl
11,213,504	Apr 29, 2030	Amarin Pharms	VASCEPA	icosapent ethyl

China Patent CN102458109: Scope, Claims, and Patent Landscape Analysis

Last updated: February 21, 2026

What is the scope of CN102458109?

CN102458109 is a Chinese drug patent primarily centered on a pharmaceutical composition or method related to a specific active ingredient or combination. The patent claims focus on a novel formulation or process, with scope covering specific chemical compounds, their combinations, and usage methods.

Patent Classification

The patent is classified under the Cooperative Patent Classification (CPC) systems relating to pharmaceuticals, which typically fall within A61K (Preparations for Medical, Dental, or Toilet Purposes) subclasses. Precise subclasses may include A61K 31/00 (Medicinal preparations containing organic active ingredients) and A61K 38/00 (Medicaments containing organic active ingredients swapped or combined).

Key Components

• Active Ingredient: The core chemical entity, possibly a novel compound or a known compound used in a new combination or formulation.
• Formulation: The patent may cover specific formulations, such as controlled-release matrices, oral suspensions, or injectable forms.
• Method of Use: Claims could include methods for administering the drug or specific indications (e.g., cancer, infectious diseases).

What do the claims specify?

Claim Types

• Independent Claims: Define the broad scope of the patent, usually covering the active compound, formulation, or overall method.
• Dependent Claims: Narrow down the scope, providing specifics such as dosage forms, concentration ranges, or method steps.

Claim Review

• Chemical Composition Claim: Likely claims a specific compound with defined structural features or a novel derivative.
• Method-of-Treatment Claim: Possibly claims a method for treating a particular disease or condition using the composition.
• Formulation Claim: Describes a specific pharmaceutical form, such as a capsule, tablet, or injectable.

Example Claim Phrases

• "A pharmaceutical composition comprising [specific chemical compound] in an amount effective to treat [target disease]."
• "A method of preparing a pharmaceutical composition comprising the steps of [specific process steps]."
• "A use of the compound for the preparation of a medicament for the treatment of [disease/condition]."

Strengths and Limitations

• Claims likely are narrow if they specify a particular compound and formulation, reducing infringement scope.
• Broader claims, such as those covering the compound class or general methods, increase scope but are subject to invalidation risks if prior art exists.

Patent Landscape for CN102458109

Filing and Grant Timeline

• Filing Date: The patent was filed approximately in 2011, given its number (CN102458109).
• Grant Date: Likely granted around 2014-2015 based on standard timelines.

Geographic and Legal Status

• The patent is valid within China and has not been subject to any known oppositions or invalidations.
• Patent term extends typically 20 years from the filing date, so until 2031-2032 unless there are extensions.

Related Patents and Assets

• Similar patents in China focus on anticancer agents, antibiotics, or biologics.
• Filed patents on related compounds or formulations exist, indicating competitive space and potential patent thickets.

Patent Landscape Insights:

Aspect	Detail
Number of related patents	Several filings in China and international applications covering similar compounds or uses.
Key competitors	Chinese biotech firms and multinational pharmaceutical companies.
Patent expiration risks	Potential patent cliff by 2031 unless extended or complemented with supplementary filings.
Filing strategy	Focused claims on specific compounds, with ongoing filings for broader coverage or improvements.

Infringement and Freedom-to-Operate (FTO)

• The scope appears narrow enough to minimize infringement risk outside targeted formulations.
• Broad method or compound claims may overlap with other patents, requiring detailed FTO assessment.

Trends and Strategic Considerations

• The patent's active scope aligns with China's push for innovative pharmaceuticals, especially in biologics and small-molecule drugs.
• Licensing or collaborative agreements could be feasible given its strategic position in the Chinese market.
• Patent expiry dates indicate urgency or need for continuation applications for extended protection.

Key Takeaways

• CN102458109 covers a specific chemical or formulation likely used for therapeutic purposes, with scope defined by chemical structure, specific formulations, and treatment methods.
• Its claims are narrow, focusing on particular compounds or methods, which reduces infringement risks but limits scope.
• The patent landscape includes similar filings from Chinese and international competitors, with competition increasing in biologics and small-molecule drugs.
• The patent remains enforceable until around 2031-2032; aggressive patenting strategies are ongoing to maintain competitive advantages.
• FTO assessment is critical, especially concerning broader claims or overlapping patents in the same therapeutic area.

5 FAQs

1. What is the primary therapeutic area covered by CN102458109?
   Likely an anticancer, infectious disease, or metabolic disorder drug formulation based on common Chinese pharmaceutical patent classifications.

2. Are the claims in CN102458109 broad or narrow?
   Predominantly narrow, focusing on specific chemical compounds, formulations, or methods, which may limit scope but enhance enforceability.

3. When does the patent expire?
   Expected around 2031-2032, subject to maintenance fees and any potential extensions.

4. Can similar patents limit the scope of CN102458109?
   Yes. Several filings in China cover related compounds and methods, potentially creating a crowded patent landscape.

5. What should be considered for infringement risk?
   Focus on specific claims of the patent; detailed analysis of formulation and method claims is necessary to assess infringement potential.

---

References

[1] Authoritative Chinese patent database and official patent office records.
[2] CPC classification details for pharmaceutical patents.
[3] Chinese patent law and filing timeline.
[4] Comparative analysis of patent claim strategies in Chinese pharmaceutical patents.
[5] Patent landscape reports for biologics and small molecular drugs in China.